FDA 优先审查 Dupixent 作为大疱性类天疱疮的潜在第一个靶向治疗。 FDA prioritizes review for Dupixent as potential first targeted treatment for bullous pemphigoid.

美国食品和药物管理局已接受对Dupixent的新申请进行优先审查,该申请用于治疗皮虫,这是一种导致水泡和病变的皮肤疾病. The FDA has accepted for priority review a new application for Dupixent to treat bullous pemphigoid, a skin condition causing blisters and lesions. 如果到2025年6月20日得到批准,Dubixent可能成为美国首例针对此病症的定向治疗,在不抑制免疫系统的情况下大大改善疾病缓解。 If approved by June 20, 2025, Dupixent could become the first targeted treatment for this condition in the US, offering significant improvements in disease remission without suppressing the immune system. 该决定基于研究数据,显示混杂物与安慰剂相比的有效性。 The decision is based on study data showing Dupixent's effectiveness compared to a placebo.